Steve O'Loughlin - Jul 1, 2022 Form 4 Insider Report for Actinium Pharmaceuticals, Inc. (ATNM)

Role
Chief Financial Officer, Director
Signature
/s/ Steve O'Loughlin
Stock symbol
ATNM
Transactions as of
Jul 1, 2022
Transactions value $
$0
Form type
4
Date filed
7/1/2022, 07:19 PM
Previous filing
Sep 3, 2021
Next filing
Dec 29, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATNM Stock Option (Right to Buy) Award $0 +256K $0.00 256K Jul 1, 2022 Common Stock 256K $4.96 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This price represents the closing price of the Company's common stock on July 1, 2022, the date of the grant.
F2 Pursuant to the terms of the Company's 2019 Stock Plan, 2% of the options will vest each month from July 1, 2022 until fully vested.